AveXis, Inc. (NASDAQ:AVXS) insider Brian K. Kaspar sold 15,000 shares of the business’s stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $94.73, for a total value of $1,420,950.00. Following the completion of the transaction, the insider now directly owns 1,826,502 shares of the company’s stock, valued at approximately $173,024,534.46. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
AveXis, Inc. (NASDAQ:AVXS) opened at $98.92 on Friday. AveXis, Inc. has a fifty-two week low of $45.33 and a fifty-two week high of $108.27.
AveXis (NASDAQ:AVXS) last announced its earnings results on Thursday, November 9th. The company reported ($1.52) EPS for the quarter, missing analysts’ consensus estimates of ($1.48) by ($0.04). During the same quarter last year, the business earned ($0.87) earnings per share. research analysts forecast that AveXis, Inc. will post -6.19 EPS for the current year.
AVXS has been the subject of several analyst reports. Jefferies Group boosted their price objective on AveXis to $118.00 and gave the company a “buy” rating in a report on Thursday, October 12th. Goldman Sachs Group reaffirmed a “buy” rating and issued a $130.00 price target on shares of AveXis in a report on Friday, October 6th. UBS reaffirmed a “buy” rating and issued a $122.00 price target (up previously from $95.00) on shares of AveXis in a report on Tuesday, October 3rd. Citigroup upped their price target on AveXis from $100.00 to $116.00 and gave the stock a “buy” rating in a report on Monday, October 2nd. Finally, Zacks Investment Research raised AveXis from a “hold” rating to a “buy” rating and set a $112.00 price target for the company in a report on Tuesday, October 24th. Four investment analysts have rated the stock with a sell rating, three have given a hold rating and thirteen have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $110.67.
Several institutional investors have recently made changes to their positions in the business. Janus Henderson Group PLC purchased a new stake in shares of AveXis in the second quarter valued at approximately $55,439,000. BlackRock Inc. grew its position in shares of AveXis by 34.7% in the second quarter. BlackRock Inc. now owns 2,301,229 shares of the company’s stock valued at $189,069,000 after purchasing an additional 592,843 shares in the last quarter. Alliancebernstein L.P. grew its position in shares of AveXis by 4,448.8% in the second quarter. Alliancebernstein L.P. now owns 564,966 shares of the company’s stock valued at $46,418,000 after purchasing an additional 552,546 shares in the last quarter. FMR LLC grew its position in shares of AveXis by 13.1% in the second quarter. FMR LLC now owns 4,705,433 shares of the company’s stock valued at $386,598,000 after purchasing an additional 544,475 shares in the last quarter. Finally, State Street Corp grew its position in shares of AveXis by 104.2% in the second quarter. State Street Corp now owns 1,000,001 shares of the company’s stock valued at $82,163,000 after purchasing an additional 510,189 shares in the last quarter. 92.88% of the stock is owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION NOTICE: This piece of content was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece of content on another domain, it was copied illegally and republished in violation of United States and international trademark and copyright legislation. The legal version of this piece of content can be accessed at https://www.dispatchtribunal.com/2017/12/17/insider-selling-avexis-inc-avxs-insider-sells-1420950-00-in-stock.html.
AveXis Company Profile
AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.
Receive News & Ratings for AveXis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis and related companies with MarketBeat.com's FREE daily email newsletter.